Professor Jean-Charles Soria
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
The gold standard end point in randomized clinical trials in metastatic breast cancer (MBC) is overall survival (OS). Although therapeutics have been approved based on progression-free survival (PFS), its use as a primary end point is controversial. We aimed to assess to what extent PFS may be used as a surrogate for OS in randomized trials of anti-HER2 agents in HER2+ MBC.
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
Cetuximab plus chemotherapy is a first-line treatment option in metastatic KRAS and NRAS wild-type colorectal cancer (CRC) patients. No data are currently available on continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression.
A genomic case study of mixed fibrolamellar hepatocellular carcinoma
Mixed fibrolamellar hepatocellular carcinoma (mFL-HCC) is a rare liver tumor defined by the presence of both pure FL-HCC and conventional HCC components, represents up to 25% of cases of FL-HCC, and has been associated with worse prognosis. Recent genomic characterization of pure FL-HCC identified a highly recurrent transcript fusion (DNAJB1:PRKACA) not found in conventional HCC.
The global decrease in cancer mortality: trends and disparities
A decrease in cancer mortality has been reported in the United States, Europe, and other high-income regions during the last two decades. Whether similar trends apply to low-to-middle income countries—and globally—is unclear.
Impact Factor increases to 9.269
Access our free collection of highly cited articles which contributed to Annals of Oncology’s new Impact Factor of 9.269
Explore papers focusing on patient-centred oncology research and care from the Oxford University Press medical journals.
The Best of 2016
Explore a collection of the best articles of 2016 from Annals of Oncology.
Why Publish with Annals of Oncology?
Give your research the global platform it deserves; submit to Annals of Oncology, one of the most widely read and cited journals in Oncology.
The latest research, on the go
Get fast and convenient access to every issue of Annals of Oncology from our app – free to download from the iTunes store.
Recommend to your library
Fill out our simple online form to recommend this journal to your library.